跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
BIMZELX - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
BIMZELX
Authorized
STANDARD
BIMZELX
UCB Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
0b6cd339f6f1c6ef
Company
UCB Canada Inc
Type
Standard
Approval Details
Approval Id
0b6cd339f6f1c6ef
Drug Approval Canada Name
BIMZELX
Product Name
BIMZELX
Status
Marketed
Status Date
2022-03-30
Original Market Date
2022-03-30
Din
02525267
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Subcutaneous
Schedule
Prescription , Schedule D
Ahfs
84:06.28
Atc Original
L04AC21 BIMEKIZUMAB
Atc Name
l 04 ac 21
Aig Number
0163399001
Company Name
UCB Canada Inc
Company Address
602, 2201 Bristol Circle, Oakville, Ontario, Canada, L6H 0J8
Active Ingredients
BIMEKIZUMAB
160 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
0b6cd339f6f1c6ef
Type
Standard
Back to Health Canada Approvals